CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 25,000 shares at $2.02 ($50,535)
- 4 Open-market buy Director bought 25,000 shares at $2.02 ($50,535)
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Open-market buy Director bought 51,214 shares at an average $2.02 ($103,340)
- 4 Open-market buy Director bought 51,214 shares at an average $2.02 ($103,340)
- 4 Open-market buy Director bought 50,000 shares at $1.93 ($96,500)
- 4 Open-market buy Director bought 50,000 shares at $1.93 ($96,500)
- 4 Open-market buy Director bought 789,473 shares at $1.90 ($1,499,999)
- 4 Open-market buy President, CEO and CFO bought 26,315 shares at $1.90 ($49,999)
- 4 Open-market buy Chief Operating Officer bought 5,263 shares at $1.90 ($10,000)
- 4 Open-market buy Chief Financial Officer bought 5,263 shares at $1.90 ($10,000)
- 4 Open-market buy Chief Medical Officer bought 2,631 shares at $1.90 ($4,999)
- 4 Open-market buy EVP and CSO bought 526 shares at $1.90 ($999)
- 4 Open-market buy Director bought 526 shares at $1.90 ($999)
- 4 Open-market buy Director bought 26,315 shares at $1.90 ($49,999)
Page 7 of 10 · 185 filings